{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:56:24Z","timestamp":1792083384446,"version":"4.4.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T00:00:00Z","timestamp":1658534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015383","name":"Foundation for Liver and Gastrointestinal Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015383","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The Dutch guideline for general practitioners (GPs) advises biannual surveillance of hepatitis B (HBV) patients and referral of every hepatitis C (HCV) patient. We aimed to study the prevalence, incidence, and the management of hepatitis B and C in primary care.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This is a retrospective cohort study using the Rijnmond Primary Care database (RPCD), including health care data of medical records of GPs of approximately 200,000 patients in the area of Rotterdam, the Netherlands. Patient records were selected based on laboratory results, International Classification of Primary Care (ICPC) codes, and free-text words.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 977 patients were included: 717 HBV, 252 HCV, and 8 HBV\/HCV coinfected patients. Between 2013 and 2019, the prevalence of HBV and HCV declined from 5.21 to 2.99\/1,000 person-years (PYs) and 1.50 to 0.70\/1,000 PYs, respectively. We observed that the majority of the patients had been referred to a medical specialist at least once (71% HBV and 89% HCV patients). However, among chronic patients, we observed that 36.2% of the HBV patients did not receive adequate surveillance by their GP (\u22652 alanine aminotransferase checks within 3 years) or a medical specialist. In addition, 44.4% of the HCV patients had no record about successful antiviral treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study demonstrated a declining prevalence in viral hepatitis B and C in primary care in the Netherlands. However, a substantial part of the patients did not receive adequate surveillance or antiviral therapy. It is therefore crucial to involve GPs in case finding and in follow-up after treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/fampra\/cmac070","type":"journal-article","created":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T06:08:47Z","timestamp":1658556527000},"page":"83-90","source":"Crossref","is-referenced-by-count":11,"title":["Epidemiology and management of hepatitis B and C in primary care in the Netherlands: data from the Rijnmond Primary Care database"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7687-4036","authenticated-orcid":false,"given":"Sylvia M","family":"Brakenhoff","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center , Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"de Man","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center , Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"de Knegt","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center , Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J E","family":"Bindels","sequence":"additional","affiliation":[{"name":"Department of General Practice, Erasmus MC, University Medical Center , Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelien I T","family":"de Schepper","sequence":"additional","affiliation":[{"name":"Department of General Practice, Erasmus MC, University Medical Center , Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,7,23]]},"reference":[{"key":"2023020910221196200_CIT0001","volume-title":"Hepatitis C factsheet","author":"World Health Organization","year":"2021"},{"key":"2023020910221196200_CIT0002","volume-title":"Hepatitis B factsheet","author":"World Health Organization","year":"2021"},{"key":"2023020910221196200_CIT0003","first-page":"D511","article-title":"[Mortality due to chronic viral hepatitis B and C infections in the Netherlands] Sterfte aan chronische hepatitis B en C in Nederland.","volume":"160","author":"Hofman","year":"2016","journal-title":"Ned Tijdschr Geneeskd"},{"key":"2023020910221196200_CIT0004","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1017\/S0950268819000359","article-title":"Chronic hepatitis B and C infections in the Netherlands: estimated prevalence in risk groups and the general population.","volume":"147","author":"Koopsen","year":"2019","journal-title":"Epidemiol Infect"},{"issue":"Suppl 1","key":"2023020910221196200_CIT0005","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/liv.13641","article-title":"Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B.","volume":"38","author":"Buti","year":"2018","journal-title":"Liver Int"},{"issue":"7","key":"2023020910221196200_CIT0006","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1111\/jgh.13294","article-title":"Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naive and nucleos(t)ide analog-experienced chronic hepatitis B patients.","volume":"31","author":"Wang","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"issue":"7","key":"2023020910221196200_CIT0007","doi-asserted-by":"crossref","first-page":"352","DOI":"10.4254\/wjh.v9.i7.352","article-title":"Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C.","volume":"9","author":"Ponziani","year":"2017","journal-title":"World J Hepatol"},{"issue":"1","key":"2023020910221196200_CIT0008","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2468-1253(18)30341-8","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial.","volume":"4","author":"Asselah","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"2023020910221196200_CIT0009","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1111\/jvh.13159","article-title":"Deferred treatment with a fixed-dose combination of sofosbuvir-velpatasvir for chronic hepatitis C virus genotype 1, 2, 4 and 6 infection.","volume":"26","author":"Asselah","year":"2019","journal-title":"J Viral Hepat"},{"issue":"10","key":"2023020910221196200_CIT0010","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1007\/s00535-018-1455-1","article-title":"Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group.","volume":"53","author":"Tsuji","year":"2018","journal-title":"J Gastroenterol"},{"issue":"11","key":"2023020910221196200_CIT0011","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1038\/s41395-018-0247-9","article-title":"On-Treatment improvement of MELD score reduces death and hepatic events in patients with hepatitis B-related cirrhosis.","volume":"113","author":"Yip","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"24","key":"2023020910221196200_CIT0012","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA"},{"key":"2023020910221196200_CIT0013","volume-title":"Global health sector strategy on viral hepatitis 2016\u20132021","author":"World Health Organization","year":"2016"},{"key":"2023020910221196200_CIT0014","volume-title":"Meer dan opsporen: Nationaal hepatitisplan: een strategie voor actie","author":"Hogenbirk","year":"2016"},{"issue":"1","key":"2023020910221196200_CIT0015","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12879-018-2988-x","article-title":"Hepatitis B\/C in the countries of the EU\/EEA: a systematic review of the prevalence among at-risk groups.","volume":"18","author":"Falla","year":"2018","journal-title":"BMC Infect Dis"},{"issue":"9","key":"2023020910221196200_CIT0016","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/23744235.2020.1766104","article-title":"Mortality from liver diseases attributable to hepatitis B and C in the EU\/EEA\u2014descriptive analysis and estimation of 2015 baseline.","volume":"52","author":"M\u00e5rdh","year":"2020","journal-title":"Infect Dis (Lond)"},{"issue":"5","key":"2023020910221196200_CIT0017","doi-asserted-by":"crossref","first-page":"e026464","DOI":"10.1136\/bmjopen-2018-026464","article-title":"Assessing testing rates for viral hepatitis B and C by general practitioners in Flanders, Belgium: a registry-based study.","volume":"9","author":"Bielen","year":"2019","journal-title":"BMJ Open"},{"issue":"6","key":"2023020910221196200_CIT0018","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.jhep.2015.01.011","article-title":"Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios.","volume":"62","author":"Wolffram","year":"2015","journal-title":"J Hepatol"},{"key":"2023020910221196200_CIT0019","volume-title":"The HEPscreen Project: screening for hepatitis B and C among migrants in the European Union (Work Package 4\u2013Report)","author":"Falla","year":"2014"},{"issue":"2","key":"2023020910221196200_CIT0020","first-page":"E51","article-title":"The role of the general practitioner in the screening and clinical management of chronic viral hepatitis in six EU countries.","volume":"57","author":"Bechini","year":"2016","journal-title":"J Prev Med Hyg"},{"key":"2023020910221196200_CIT0021","article-title":"NHG-Standaard Virushepatitis en andere leveraandoeningen. Versie 4.0","author":"Numans","year":"2016"},{"key":"2023020910221196200_CIT0022","first-page":"1","article-title":"Data Resource Profile: The Integrated Primary Care Information (IPCI) database, The Netherlands.","author":"de Ridder","year":"2022","journal-title":"Int J Epidemiol"},{"key":"2023020910221196200_CIT0023","author":"Centraal Bureau voor de Statistiek.","year":"2021"},{"key":"2023020910221196200_CIT0024","author":"Centraal Bureau voor de Statistiek."},{"key":"2023020910221196200_CIT0025","volume-title":"NHG-tabel 24-ICPC-Versie 8","author":"Nederlands Huisartsengenootschap.","year":"2020"},{"issue":"1","key":"2023020910221196200_CIT0026","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1186\/s12889-019-6820-3","article-title":"Calculating incidence rates and prevalence proportions: not as simple as it seems.","volume":"19","author":"Spronk","year":"2019","journal-title":"BMC Public Health"},{"issue":"3","key":"2023020910221196200_CIT0027","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.","volume":"2","author":"Polaris Observatory HCV Collaborators.","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"2023020910221196200_CIT0028","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/liv.14324","article-title":"Global timing of hepatitis C virus elimination in high-income countries.","volume":"40","author":"Razavi","year":"2020","journal-title":"Liver Int"},{"issue":"5","key":"2023020910221196200_CIT0029","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/joim.12740","article-title":"Treatment as prevention for hepatitis C (TraP Hep C)\u2014a nationwide elimination programme in Iceland using direct-acting antiviral agents.","volume":"283","author":"Olafsson","year":"2018","journal-title":"J Intern Med"},{"issue":"5","key":"2023020910221196200_CIT0030","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/jvh.13063","article-title":"Monitoring the hepatitis C epidemic in England and evaluating intervention scale-up using routinely collected data.","volume":"26","author":"Harris","year":"2019","journal-title":"J Viral Hepat"},{"issue":"3","key":"2023020910221196200_CIT0031","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/17474124.2018.1424541","article-title":"Hepcare Europe\u2014bridging the gap in the treatment of hepatitis C: study protocol.","volume":"12","author":"Cullen","year":"2018","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"6","key":"2023020910221196200_CIT0032","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12445-021-1140-0","article-title":"Case-finding voor hepatitis B en C bij pati\u00ebnten uit risicolanden.","volume":"64","author":"Generaal","year":"2021","journal-title":"Huisarts en wetenschap"},{"issue":"4","key":"2023020910221196200_CIT0033","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/jmv.20486","article-title":"Changes in risk behavior and dynamics of hepatitis C virus infections among young drug users in Amsterdam, the Netherlands.","volume":"77","author":"van de Laar","year":"2005","journal-title":"J Med Virol"},{"key":"2023020910221196200_CIT0034","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1477-7517-7-25","article-title":"Seroprevalence of HIV, hepatitis b, and hepatitis c among opioid drug users on methadone treatment in the netherlands.","volume":"7","author":"Schreuder","year":"2010","journal-title":"Harm Reduct J"},{"key":"2023020910221196200_CIT0035","volume-title":"Epidemiological assessment of hepatitis B and C among migrants in the EU\/EEA","author":"European Centre for Disease Prevention and Control.","year":"2016"},{"issue":"5","key":"2023020910221196200_CIT0036","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/QAD.0000000000000126","article-title":"Trends in hepatitis C virus infections among MSM attending a sexually transmitted infection clinic; 1995\u20132010.","volume":"28","author":"Urbanus","year":"2014","journal-title":"AIDS"},{"issue":"2","key":"2023020910221196200_CIT0037","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1017\/S0950268807008205","article-title":"Hepatitis B virus transmission in The Netherlands: a population-based, hierarchical case-control study in a very low-incidence country.","volume":"136","author":"Hahn\u00e9","year":"2008","journal-title":"Epidemiol Infect"},{"issue":"5","key":"2023020910221196200_CIT0038","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: final update of the series.","volume":"73","author":"European Association for the Study of the Liver; Clinical Practice Guidelines Panel C; EASL Governing Board representative.","year":"2020","journal-title":"J Hepatol"},{"key":"2023020910221196200_CIT0039","first-page":"D2047","article-title":"[Follow-up diagnostics, referral and follow-up of hepatitis B and C patients] Vervolgdiagnostiek, follow-up en verwijzing van pati\u00ebnten met hepatitis B en C.","volume":"162","author":"Hofman","year":"2018","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"1","key":"2023020910221196200_CIT0040","doi-asserted-by":"crossref","first-page":"e000396","DOI":"10.1136\/bmjgast-2020-000396","article-title":"Hepatitis C elimination in the Netherlands (CELINE): study protocol for nationwide retrieval of lost to follow-up patients with chronic hepatitis C.","volume":"7","author":"Isfordink","year":"2020","journal-title":"BMJ Open Gastroenterol"},{"issue":"596","key":"2023020910221196200_CIT0041","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.3399\/bjgp12X630115","article-title":"Follow-up of mild alanine aminotransferase elevation identifies hidden hepatitis C in primary care.","volume":"62","author":"Helsper","year":"2012","journal-title":"Br J Gen Pract"}],"container-title":["Family Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/fampra\/article-pdf\/40\/1\/83\/49136737\/cmac070.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/fampra\/article-pdf\/40\/1\/83\/49136737\/cmac070.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T14:32:52Z","timestamp":1675953172000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/fampra\/article\/40\/1\/83\/6648930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,23]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,7,23]]},"published-print":{"date-parts":[[2023,2,9]]}},"URL":"https:\/\/doi.org\/10.1093\/fampra\/cmac070","relation":{},"ISSN":["1460-2229"],"issn-type":[{"value":"1460-2229","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2022,7,23]]}}}